The aim of these documents is to minimise the prescribing of medicines that offer a limited clinical benefit to patients and where more cost effective treatments may be available.
Five medicines/medicine groups have been identified for the purposes of this document: co-proxamol, lidocaine plasters, tadalafil once daily preparations, liothyronine and doxazosin modified release tablets.
⇩ Medicines identified as Low Priority for Funding in NHS Wales — Paper 1 704KB (PDF) |
(Published October 2017 [Section on 'liothyronine' updated and addendum added in November 2019])
Four medicines/medicine groups have been identified for the purposes of this document: omega-3 fatty acid compounds, oxycodone and naloxone combination product, paracetamol and tramadol combination product and perindopril arginine.
⇩ Medicines identified as Low Priority for Funding in NHS Wales — Paper 2 578KB (PDF) |
(Published December 2018 [Section on 'omega-3 fatty acid compounds' updated in September 2022])
This is the third paper in the ongoing initiative, previously entitled Medicines Identified as Low Priority for Funding in NHS Wales.
This Low Value for Prescribing document has been developed to provide healthcare professionals with information to minimise the prescribing of medicines that offer a limited clinical benefit to patients and where more cost-effective treatments may be available. Nine items/item groups have been identified for the purposes of this document. These are:
⇩ Items Identified as Low Value for Prescribing in NHS Wales — Paper 3 309KB (PDF) |
(Published February 2020 [Updated March 2022])